Zobrazeno 1 - 10
of 1 149
pro vyhledávání: '"59"'
Autor:
Chunxia Dong, Li Zhang, Zhuanzhen Zheng, Li-Hong Hou, Yalin Wang, Yujin Lu, Zhenhua Qiao, Wenliang Chen, Bo Jiang, Rong Gong, Yanping Ma, Lianrong Xu, Guoxia Li
Publikováno v:
Blood. 118:4923-4923
Abstract 4923 Objective To explore the safety and clinic therapeutic effects of using tumor activated dendritic cells (DC) accompanied cytokine induced killer (CIK) in order to feinforce opposing anti-tumor function and to eliminate minimal residual
Autor:
Ayumu Kubota, Atae Utsunomiya, Masahito Tokunaga, Nobuaki Nakano, Mayumi Tokunaga, Shogo Takeuchi, Takahiro Itoyama, Torahiko Makino, Yoshifusa Takatsuka
Publikováno v:
Blood. 118:4483-4483
Abstract 4483 Adult T-cell leukemia/lymphoma (ATLL) is one of human T-cell leukemia virus type 1 (HTLV-1) related diseases and is usually characterized as CD4+CD8-CD25+ peripheral T-cell lymphoma with very poor prognosis. Although many chemotherapeut
Autor:
Françoise Boyer, Joelle Guilhot, Emmanuel Gyan, Jean Christophe Ianotto, Cony Makhoul, Emmanuel Raffoux, Jean Gunecht, Jean-François Viallard, Lydia Roy, Franck E. Nicolini, Benoit de Renzis, Laurence Legros, Stéphane Giraudier
Publikováno v:
Blood. 116:1974-1974
Abstract 1974 Background: Conventional therapeutic guidelines in essential thrombocytemia (ET) are based on established criteria of higher incidence of vascular complications: age more than 60 years, history of thrombosis, platelets more than 1000–
Autor:
Maria N. Dimopoulou, Maria K. Angelopoulou, Sotirios Sachanas, Theodoros P. Vassilakopoulos, Xanthi Yiakoumis, Penelope Korkolopoulou, Christina Kalpadakis, Flora N. Kontopidou, Marina P. Siakantaris, Styliani I. Kokoris, Helen A. Papadaki, Gerassimos A. Pangalis, Maria Moschogiannis, Evangelia M. Dimitriadou, Marie-Christine Kyrtsonis
Publikováno v:
Blood. 118:2712-2712
Abstract 2712 Treatment of splenic marginal zone lymphomas (SMZL) is traditionally based on splenectomy. However, preliminary data suggest that rituximab monotherapy is highly effective in SMZL patients. The aim was to assess the efficacy of rituxima
Publikováno v:
Blood. 104:825-825
Conventional allogeneic HSC transplantation is limited by lack of rapidly available, HLA-matched donors & excess transplant-related mortality (TRM) in high-risk adults. Therefore, we investigated the combined use of unrelated donor UCB, utilizing 2 u
Autor:
Hani Hassoun, Agne Paner, Paula Rodriguez-Otero, Amitabha Mazumder, Michele Cavo, Noemi Puig, Christopher Maisel, Maxim Norkin, Paul G. Richardson, Maria-Victoria Mateos, Adrián Alegre Amor, Anastasios Raptis, Cyrille Touzeau, Marcus Thuresson, Johan Harmenberg, Alessandra Larocca, Albert Oriol, Bengt Gustavsson, John W. Hiemenz, Omar Nadeem, Xavier Leleu, Joan Blade Creixenti
Publikováno v:
Blood. 136:41-43
Background: In patients with relapsed/refractory multiple myeloma (RRMM), 29%-59% have high-risk (HR) cytogenetic abnormalities that are associated with poor treatment outcomes (Kumar et al. Leukemia. 2017;31:2443; Gandhi et al. Leukemia. 2019;33:226
Autor:
Ahmad S. Alotaibi, Tapan M. Kadia, Courtney D. DiNardo, Hagop M. Kantarjian, Wilmer Flores, Guillermo Garcia-Manero, Jorge E. Cortes, Jairo Matthews, Elias Jabbour, Steven M. Kornblau, Naval Daver, Michael Andreeff, Padmanee Sharma, Mark Brandt, Jing Ning, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Hussein A. Abbas, James P. Allison, Naveen Pemmaraju, Nicholas J. Short, Marina Konopleva, Sherry Pierce, Koichi Takahashi, Farhad Ravandi, Sreyashi Basu, Gautam Borthakur
Publikováno v:
Blood. 136:43-45
Background: Blockade of PD-1/PD-L1 pathways enhances anti-leukemic responses in pre-clinical studies. PD1 inhibition alone had limited clinical activity in AML. CLTA4 inhibition demonstrated encouraging single-agent CR's in postASCT patients (pts), e
Publikováno v:
Blood. 136:36-37
Introduction: Limited real-world studies exist on the management of relapsed/refractory (R/R) classical Hodgkin's lymphoma (cHL) patients (pts) who failed autologous stem transplant (auto-SCT) and their subsequent healthcare resource utilization (HRU
Autor:
Viola Poeschel, Hervé Tilly, Marita Ziepert, Joerg Hoffmann, Hervé Maisonneuve, Lorenz Thurner, Bettina Altmann, Roch Houot, Corinne Haioun, Steven Le Gouill, Marie Maerevoet, Martin Dreyling, Andrea Kerkhoff, Thomas P. Weber, Gerhard Held, Stephan Stilgenbauer, Marc André
Publikováno v:
Blood. 136:32-32
Background: Anti-PD1 antibodies have the potential to increase rituximab-mediated effector mechanisms, to target the microenvironment and PD-1 in aggressive Non-Hodgkin Lymphoma (NHL). Addition of Nivolumab (Nivo) might increase efficacy of chemother
Autor:
Martin Dunbar, Uma Borate, Guillermo Garcia-Manero, Poonam Tanwani, Johannes E. A. Wolff, Jacqueline S. Garcia, Jason Harb, Meagan A. Jacoby, Florian Nolte, Maria R. Baer, Olatoyosi Odenike, Andrew H. Wei, Pierre Peterlin, Joseph G. Jurcic, Uwe Platzbecker, Ying Zhou, Chun Yew Fong, Wan-Jen Hong
Publikováno v:
Blood. 134:568-568
Introduction Hypomethylating agents (HMAs), azacitidine (Aza) or decitabine, are standard treatment (Tx) for patients (pts) with higher-risk myelodysplastic syndrome (HR-MDS) not candidates for immediate allogeneic hematopoietic stem cell transplanta